This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Q2 FY27 Results: Revenue Rs 417 Cr, PAT Rs 28 Cr; H1 PAT surges to Rs 45 Cr
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.9 pts more than Nifty Microcap 250 and 9.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Solara Active Pharma reported strong Q2 FY27 results. Consolidated revenue rose about 33% YoY to Rs 417.34 crores from Rs 313.54 crores. H1 revenue grew to Rs 798.94 crores vs Rs 632.69 crores. Q2 PAT was Rs 28.46 crores vs a loss of Rs 10.10 crores last year. H1 PAT surged to Rs 44.77 crores from Rs 0.42 crores. EPS for Q2 was Rs 5.92. Exceptional item of Rs 4.50 crore loss on Vizag plant CWIP noted. Deloitte issued unmodified review conclusion.
Sharp turnaround from losses to strong profit, revenue up 33% YoY. Positive for shareholders though accumulated losses of Rs 274 crores remain.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹417.3 Cr | ₹313.5 Cr | +33.1% |
| Operating profit | ₹32.42 Cr | −₹10.59 Cr | turned positive |
| Profit after tax | ₹28.46 Cr | −₹10.10 Cr | turned positive |
| EBITDA margin | 17.3% | 11.1% | +6.2 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.